Former General Mills Executive Named CEO Of Recombinetics
Recombinetics announced a number of executive suite changes and board of director additions late Wednesday.
Dr. Scott Fahrenkrug, who founded the St. Paul-based livestock gene-editing company in 2008, will no longer be CEO. Fahrenkrug will instead serve as chief scientific officer and executive chairman of the board.
His replacement will be Ian Friendly, a more than 30-year member of General Mills’ executive leadership team. Most recently, he was the executive vice president and chief operating officer of U.S. retail for the Golden Valley-based food conglomerate. Friendly will lead Recombinetics in the completion of its current private equity round, while also preparing the company for global product expansion possibilities.
“I’m pleased to be joining a company that is on the leading edge of transforming human health and finding solutions to feed our growing population,” Friendly said in a statement. “The scientific discoveries occurring in our labs, and our strategic partnerships with leading research universities and medical centers, will enable us to accelerate the search for cures and pharmaceutical compounds to save human lives—while finding more humane ways to care for animals.”
Tammy Lee Stanoch will also be joining Recombinetics as its new chief corporate affairs officer. Stanoch joins the company with over 15 years corporate affairs experience with companies such as Carlson, the University of Minnesota Foundation and Delta Air Lines.
Amid the leadership shuffle, six members were added to the company’s board of directors. The new members come from a variety of medical and technology backgrounds:
- Perry Hackett, co-founder of the Center for Genome Engineering at the University of Minnesota
- Wendell King, CEO of King Consulting and former vice president of Medtronic
- Mark Kroll, chief technology officer at St. Jude Medical’s cardiac rhythm management division
- Robert Switz, chairman of the board for Micron Inc.
- Mitch Abrahamsen, senior vice president of research and development at Cobb-Vantress
- Paul Olson, chairman of the board of Entegris, Inc.